null

null

null

null

null

null

null

null

null

Pre-revenue clinical-stage biotech; minimal debt, primarily equity-financed; ~$400M+ cash runway; near-zero leverage ratio

Low direct sensitivity; no significant floating-rate debt; higher rates increase opportunity cost of cash holdings and raise future equity dilution risk

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

API synthesis reliance on specialized CMOs in China/India; geopolitical chokepoints are US-China trade restrictions and Indian API export controls

No international revenue yet; clinical-stage US-focused company; sovereign currency devaluation exposure is effectively zero currently

Entirely US-based operations and revenue; no material international commercial presence; single-country risk profile

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on single or limited CMO/CRO partners for sevasemten and EDG-7500 manufacturing; substitution would cause significant clinical delays

Clinical-stage biopharmaceutical; cloud disruption would impair R&D informatics and trials management but not directly halt drug development

No secondary business model; pure-play drug development with potential future royalty/licensing revenue post-approval

Low API coupling risk; primarily uses standard clinical data platforms (Medidata, Veeva); no proprietary API lock-in identified

Not applicable; revenue model is drug sales/licensing, not an investment contract; Howey Test risk is negligible

Very High

Moderate GDPR/CCPA exposure via clinical trial patient data from EU sites; requires robust data handling agreements with CROs

Low antitrust risk; early-stage company with no market dominance; cardiac myosin inhibitor space is competitive with BMS/MyoKardia

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Currently zero commercial revenue; future model will be transactional drug sales plus potential milestone-based licensing deals

Primary monetization via direct drug sales post-approval and partnership/licensing milestones; no subscription revenue component

Orphan/specialty drug pricing expected; obstructive HCM comparables (mavacamten ~$80K/year) suggest $50K-$100K annual pricing power

Moderate-to-high; differentiated mechanism and once-daily dosing vs. mavacamten could command premium or parity pricing with strong payer leverage

Target gross margins of 80-90% typical for specialty oral small-molecule drugs post-commercialization

No free-rider problem applicable; prescription drug model with payer/prior-auth gatekeeping; patient adherence is primary retention risk

Revenue growth will be sublinear to headcount post-approval; commercial launch requires sales force build but manufacturing is outsourced

Marginal cost of incremental revenue is low post-approval given outsourced manufacturing; primary fixed cost is commercial infrastructure

Not applicable; no franchise network; direct pharma model

At 10x scale, CAC per cardiologist decreases via rep efficiency; HCM patient population (~100K-175K US) caps absolute scale potential

No meaningful network effects; prescription drug adoption driven by clinical evidence and physician education, not user network density

-30.4% Return on Assets (Negative equity)

High recession resistance; HCM is serious cardiac condition requiring treatment regardless of economic cycle; reimbursement via insurance buffers price sensitivity

Cardiologists and electrophysiologists treating hypertrophic cardiomyopathy patients; concentrated among ~5,000-8,000 US HCM specialists

Potential expansion to dilated cardiomyopathy and heart failure with reduced ejection fraction patient populations via EDG-7500 program

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

Capital allocated entirely to R&D pipeline advancement; no legacy infrastructure; outsourced manufacturing means minimal capex; burn ~$150-200M annually

0001710072

EWTX